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New biomarkers are needed for discriminating active tuberculosis (TB) from latent TB 
infection (LTBI), especially in vulnerable groups representing the major diagnostic chal-
lenge. This pilot study was carried out to explore the diagnostic potential of selected 
genes, IFN-γ, IL-17, IL-4, and FoxP3, associated with TB immunity and immunopa-
thology. IFN-γ, IL-17, IL-4, and FoxP3 mRNA expression levels were measured by 
quantitative reverse transcription PCR (RT-qPCR) from antigen-stimulated peripheral 
blood mononuclear cells of patients with active TB (n = 25); patients with miscellaneous 
inflammatory disorders and concomitant LTBI (n = 20), rheumatoid arthritis (RA) being 
the most predominant in the group (n = 11); and in healthy Bacillus Calmette–Guérin 
(BCG) vaccinees (n = 8). While the levels of FoxP3 mRNA did not differ between the 
tested groups, the cumulative expression levels of purified protein derivative-stimulated 
IFN-γ, IL-17, and IL-4 mRNAs were found to distinguish active TB from the whole group 
of LTBI with 48% sensitivity and 85% specificity. When restricting the LTBI group to 
RA cases only, the sensitivity was 56% and specificity 100%. When interpreting the 
result as positive in at least one of the mRNAs IFN-γ, IL-17, or IL-4, sensitivity of 64% 
and specificities of 75% (heterogeneous group of LTBI) or 100% (LTBI with RA) were 
achieved. Moderate discrimination of active TB from LTBI with miscellaneous inflamma-
tory underlying conditions by using combined quantitative expression of IFN-γ, IL-17, 
and IL-4 mRNA seems not to be of high diagnostic potential.
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inTrODUcTiOn
T cell-mediated immunity through the Th1-arm of the immu-
nologic system serves an important function in controlling 
tuberculosis (TB). Almost everyone infected with Mycobacterium 
tuberculosis (Mtb) produces IFN-γ and TNF-α, yet these cytokines 
cannot confer protection against clinical disease (1).
T cell-based IFN-γ release assays (IGRAs) developed a decade 
ago are the first diagnostic tests conceived after the century-old 
tuberculin skin test for identification of contact with Mtb (2). 
Although not capable of discriminating active TB from latent TB 
infection (LTBI), IGRAs are used in areas with low TB incidence 
as a supplemental method in subjects with symptoms suggestive 
of TB. A negative IGRA test in an immunocompetent patient 
indicates that active TB is improbable. (3) From the diagnostic 
point of view, patients with miscellaneous inflammatory muscu-
loskeletal disorders responding poorly to conventional therapy 
present a great diagnostic challenge. In these patients, LTBI 
should be excluded before the commencement of the so-called 
biological therapy with, e.g., TNF-α blockers, due to the risk of 
TB reactivation (4).
The diagnostic potential of T cell subsets other than Th1 and 
its markers is not yet fully exploited. For example, the recently 
described Th17 subset (5) producing proinflammatory cytokine 
IL-17 promotes chemokine expression and the recruitment of 
neutrophils and stimulates T cells producing IFN-γ in the lungs. 
This cytokine is important in early granuloma formation, i.e., the 
protective mechanism to wall off an infection (6). However, when 
neutrophil recruitment gets too extensive and IL-17 is secreted 
in excess, the fine balance is shifted to “overwhelmed” immune 
response, resulting in tissue damage and necrosis inside the 
granuloma (7).
Regulatory T cells (Tregs) expressing the forkhead box P3 
(FoxP3) serve to limit the effector response to the infectious 
agent, which may result in a failure of infection control. These 
cells have proved to minimize tissue damage and immunopatho-
logical effects caused by effector mechanisms. (8) For example, 
in a murine model of TB, Tregs delayed the recruitment of 
Mtb-specific effector T cells to the lungs, thus impairing immune 
protection (9). Indeed, higher levels of Tregs in peripheral blood 
and the lungs of patients with active TB compared to healthy 
controls were described (10, 11).
Th2 cells have a distinct role in the pathogenesis of TB. The 
excessive production of IL-4 may attenuate the Th1 response and 
lead to severe immunopathological consequences (12). Elevated 
levels of IL-4 mRNA have been detected from peripheral blood 
mononuclear cells (PBMCs) of patients with active TB (13) and 
those LTBI alike (14). On the other hand, IL-4δ2, which is an 
antagonist of IL-4 and a truncated variant of IL-4, has proved 
elevated in LTBI and in cured TB (13, 15, 16). The ratio of IL-4 
to IL-4δ2 has been suggested to function as a reliable marker of 
treatment efficacy (13, 16).
This study was undertaken to explore the diagnostic value 
of IFN-γ, IL-4, IL-17, and FoxP3 gene expression levels. We 
set out to investigate whether the quantitative expression of 
these biomarkers differs between groups with active TB and 
LTBI.
MaTerials anD MeThODs
ethical statements
The study protocol was approved by the Southwest Finland dis-
trict Ethical Committee (DroNo 47/180/2009) and by Helsinki 
and Uusimaa Hospital district (149/2010). All patients provided 
written informed consent.
study subjects
Nine milliliters of whole heparinized blood was collected from 
25 patients with active TB group, 20 with LTBI (LTBI group), and 
8 healthy volunteers with a history of Bacillus Calmette–Guérin 
vaccination in their childhood (BCG group). Subjects with LTBI 
were further subdivided. The rheumatoid arthritis (RA) subgroup 
included the patients with RA (n =  11). The MISC subgroup 
(n = 9) includes the patients with miscellaneous inflammatory 
conditions (one of each: vasculitis, ankylosing spondylitis, myia-
sis, mycoplasma infection, streptococcal skin infection, unknown 
skin infection, tonsillitis, COPD, and weakness of skin sensation). 
IGRA tests were performed as a diagnostic work-up in LTBI group, 
and active TB was excluded in all. In the TB group, 22 patients had 
been diagnosed with pulmonary TB and 3 with extrapulmonary 
TB. Only one pulmonary TB patient was diagnosed on the basis 
of clinical presentation, radiological findings consistent with TB, 
and a good response to anti-TB treatment. All other TB patients 
were diagnosed by Mtb isolation. The blood samples of all TB 
patients were drawn not more than 2 weeks after initiation of anti-
TB treatment (median: 7 days, range: 0–14 days). LTBI diagnosis 
was composed on the basis of a positive IGRA result and a his-
tory of TB exposure, with neither radiological nor clinical signs 
of active TB. In the BCG group, LTBI was excluded by negative 
IGRA result. The demographic and clinical characteristics of 
the study subjects are presented in Table 1. Previous treatment 
schemes for RA are shown in Table 2. All enrolled patients and 
healthy subjects were HIV negative.
Quantitative reverse Transcription Pcr
Peripheral blood mononuclear cells were isolated with Ficoll 
paque (Amersham Biosciences AB, Uppsala, Sweden) cen-
trifugation and stored in liquid nitrogen until use or stimulated 
immediately. A total of the cells were incubated in RPMI-10% 
FCS (Sigma–Aldrich, Saint Louis, MO, USA) with purified pro-
tein derivative (PPD) [Statens serum institute (SSI)] (10 μg/ml), 
pool of culture filtrate protein 10 (CFP-10), and early secretory 
antigenic target (ESAT-6) peptides (Oxford Immunotec, Oxford, 
UK) and without antigen for 22  h (17, 18) at 37°C, 5%CO2 
and lysed with TRI Reagent® (Molecular research center, Inc., 
Cincinnati, OH, USA). mRNA was extracted with RNeasy mini 
kit (Qiagen, Dusseldorf, Germany) according to manufacturer’s 
instructions and transcribed using AMV reverse transcriptase 
(New England Biolabs, Ipswich, England), Oligo(dT)23 primers 
(Sigma–Aldrich), and dNTP Mix (Thermo Scientific, Waltham, 
MA, USA) in a final volume of 20 μl. RiboLock RNase Inhibitor 
was used (thermo scientific). Amplification was performed in a 
total volume of 20 μl using the Power SYBR® Green PCR Master 
Mix (Life Technologies Ltd., Paisley, UK) as instructed. The vali-
dated (19) housekeeping gene, human ribosomal protein (HuPO), 
TaBle 2 | characteristics of lTBi patients with a rheumatic disease.
gender Diagnosis Disease  
duration (years)
Biological  
medicine (months)
Prednisone  
dose (mg/day)
DMarDsa crPb mg/l esrc  
mm/h
M RAd (M05.8) 26 Etanercept (32) 5 Mtxe, SASPf, and HCQg 3 17
F RA (M06.0) 28 Etanercept (59) 5 – 11 36
M RA (M05.8) 16 –k 10 Mtx 87 39
F RA (M06.0) 9 Etanercept (1) – – 10 8
F RA (M05.8) 6 – 5 Mtx, leflunomide, and HCQ <3 2
F RA (M05.8) 20 Rituximab (12) 5 – 29 34
F JRAh (M08.0) 64 Rituximab (23) 7.5 – 18 13
F RA (M05.8) 8 – 5 Leflunomide 71 41
F RA (M05.8) 8 – – SASP 13 22
M RA (M05.8) 7 Rituximab (24) 5 Mtx and HCQ 72 57
M Vascultis (L95.8) 1 – 5 HCQ 7 5
M RA (M05.8) 18 – 7.5 Mtx and CyAi <3 26
F SPAj (M45) 4 Golimumab (1) – Mtx and SASP 4 12
aDisease-modifying antirheumatic drug.
bC-reactive protein.
cErythrosyte sedimentation rate.
dRheumatoid arthritis.
eMethotrexate.
fSulfasalazine.
gHydroxychloroquine.
hJRA, juvenile rheumatoid arthritis.
iCyclosporine.
jSPA ankylosing spondylitis.
kEtanercept stopped 9 months earlier (used for 21 months).
TaBle 1 | clinical and demographical data of enrolled subjects.
Patient groups n age range (mean) Female (n) % aFB pos. (n) % culture pos (n) % igra pos (n) %
Active TB (TB) 25 24–87 (44) 10 (40) 19 (76) 24 (96) n/d
Active TB, pulmonary (TB) 22 26–87 (45) 8 (36) 19 (86) 21 (95) n/d
Active TB, extrapulmonary (TB) 3 24–61 (36) 2 (67) 0 (0) 3 (100) n/d
Latently infected (LTBI) 20 34–77 (61) 10 (50) n/d n/d 20 (100)
Rheumatic diseasesa 13 49–77 (65) 8 (62) n/d n/d 13 (100)
Miscellaneous conditionsb 7 34–64 (56) 2 (29) n/d n/d 7 (100)
Healthy BCG vaccinees (BCG) 8 25–50 (34) 6 (75) n/d n/d 0 (0)
n/d, not defined.
aRA, rheumatic arthritis (n = 10); JRA, juvenile rheumatic arthritis (n = 1), vasculitis (n = 1), SPA ankylosing spondylitis (n = 1).
bInfection other than TB (n = 5), COPD (n = 1), weakness of skin sensation (n = 1).
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was used to normalize the mRNA values. The primers used 
included HuPO forward, 5′-GCAATGTTGCCAGTGTCTGT-3′, 
HuPO reverse, 5′-GCCTTGACCTTTTCAGCAAG-3′; IFN-γ 
forward, 5′-ATTCGGTAACTGACTTGAATGTCC-3′, IFN-γ 
reverse, 5′-CTCTTCGACCTCGAAACAGC-3′ (20); IL-4 
forward, 5′-CGA GTT GAC CGT AAC AGA CAT-3′, IL-4 
reverse, 5′-CGT CTT TAG CCT TTC CAA GAAG-3′; IL4δ2 
forward, 5′-CAGAGCAGAAGAACACAACTG, IL4δ2 reverse, 
5′-GTCTTTAGCCTTTCCAAGAAG-3′ (15); IL-17 forward, 
5′-GGA CTG TGA TGG TCA ACC TGA-3′, IL-17 reverse, 
5′-TCA TGT GGT AGT CCA CGT TCC-3′ (21); FoxP3 
forward, 5′-ACCTGGAAGAACGCCATC-3′, FOXP3 reverse, 
5′-TGTTCGTCCATCCTCCTTTC-3′ (22). qPCR analysis was 
performed with iCycleriQ™ Real-Time PCR detection system 
(Biorad, Hercules, CA, USA). Forty cycles were run with initial 
melting step of 5 min at 95°C followed by cycles of 45 s at 95°C, 
45  s at 60°C, and 45  s at 72°C. Specificity of the primers was 
ensured once with gel electrophoresis and later with melting 
curve analysis. The results were analyzed with comparative Ct 
method 2ΔΔCt (23).
statistical analysis
The data were analyzed with GraphPad Prism version 6.0 
(GraphPad Software, Inc., San Diego, CA, USA.). Mann–Whitney 
U-test was used for testing the differences between the groups; 
p < 0.05 was considered significant. Cutoff points with highest 
combined sensitivity and specificity were calculated with receiver 
operating-characteristic (ROC) curves and discriminative ability 
with area under the curves (AUCs).
resUlTs
selection of genes for Further evaluation
We first tested the ability of PPD to stimulate different genes and 
the discriminative power of selected genes by analyzing five sam-
ples from each study group. In these pilot experiments, mRNA 
FigUre 1 | cFP-10-esaT-6 peptide pool stimulated mrna expression. Fold increase in IFN-γ (a) and IL-4 (B) expression in TB (n = 11), LTBI (n = 6) and 
BCG (n = 4) groups. Medians of the groups are shown with horizontal bars.
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expression levels of IFN-γ (p = 0.095), IL-17 (p = 0.1032), IL-4 
(p = 0.087), and FoxP3 (p = 0.286) were higher in the TB than in 
the LTBI group (data not shown).
cFP-10 and esaT-6 Peptide Pools as 
gene expression stimulators
mRNA expression levels of IFN-γ, IL-17, IL-4, and FoxP3 were 
analyzed after stimulation with a pool of peptides derived from 
CFP-10 and ESAT-6. Peptides stimulated IFN-γ and IL-4 mRNA 
expression, but difference was not observed between the medians 
of the IFN-γ expression in the TB and the LTBI groups (Figure 1). 
In the TB group, the median of IL-4 mRNA expression appeared 
higher than that in the LTBI group, yet the difference did not 
prove statistically significant (Figure 1). The peptide antigen 
stimulation resulted in the expression of IL-4 mRNA in two 
LTBI patients also, and those were diagnosed with RA more 
than 20  years ago. Both patients received biological treatment 
during our investigation. As expected, neither IFN-γ nor IL-4 
mRNA expression levels were found elevated in the BCG group 
(Figure 1). Peptide stimulation induced neither FoxP3 nor IL-17 
expressions in any of the study groups (data not shown).
Testing of Different combinations of 
selected genes as Potential Biomarkers 
to Differentiate active TB from lTBi
For the final assessment, IFN-γ, IL-17, IL-4, and FoxP3 genes 
and PPD stimulation were selected. Altogether 25, 20, and 
8 samples from TB, LTBI, and BCG groups were analyzed, 
respectively. A comparison of the FoxP3 gene expression 
between the TB and LTBI groups showed highly overlapping 
levels and no differences in the medians (data not shown). After 
PPD stimulation, in the TB group, the IFN-γ, IL-17, and IL-4 
mRNA expression levels were higher than in the LTBI group 
(Figures 2A–C), yet these differences did not prove statistically 
significant (Table 3). The cutoff levels for the IFN-γ, IL-17, and 
IL-4 assays to discriminate the TB from the LTBI group were 
assessed with ROC curve and AUC analyses (Figures  2A–C; 
Table  3). The cutoffs were set at the levels with at least 85% 
specificity. In the BCG group, two subjects reacted over the 
cutoff in the IFN-γ expression assay, but none in the IL-17 
or IL-4 expression. Altogether, 11/25, 8/25, and 8/25 subject 
from the TB group and 3/20, 2/20, and 2/20 from the LTBI 
groups produced positive results for the IFN-γ, IL-17, and 
IL-4 expression levels, respectively. Next, the discriminative 
ability of the cumulative expression of IFN-γ, IL-17, and IL-4 
was analyzed (Table 3). No statistically significant differences 
between the groups were observed with any of the combina-
tions tested. However, a sensitivity of 48% and a specificity of 
85% were achieved when calculating the cumulative expression 
of IFN-γ, IL-17, and IL-4 or IFN-γ and IL-17 mRNAs (Table 3). 
Alternatively, any positive result in at least one test of IFN-γ, 
IL-17, or IL-4 resulted in a sensitivity of 64% and a specificity 
of 75%. Positive results in at least in IFN-γ or IL-4 produced a 
sensitivity of 60% and the specificity of 80%. The results of all 
the tested combinations are shown in Table 3.
Various combinations of selected genes 
as Potential Biomarkers to Differentiate 
active TB from lTBi in Patients with ra or 
with Miscellaneous inflammatory 
conditions
Quantitative expression of IFN-γ, IL-17, and IL-4 mRNAs to 
differentiate active TB from LTBI in an RA or MISC groups was 
investigated. A significant difference in IFN-γ (p < 0.05) and IL-4 
(p < 0.05) mRNA expression levels was found between the TB and 
the RA groups (Figures 3A–C; Table 4). In IL-17 mRNA analysis, 
the difference between TB and RA groups was not statistically 
significant (p =  0.264), yet there was a positive trend toward 
discrimination (Table 4). When the MISC and the TB group were 
compared, neither the differences in the cytokine levels or their 
combinations reached statistical significance (Table  4). In  the 
MISC group, the highest IFN-γ mRNA expression levels were 
found in patients with tonsillitis and unknown skin infection. 
IL-17 mRNA expression levels were increased in patients with 
myiasis and ankylosing spondylitis, and IL-4 in patients with 
vasculitis and unknown skin infection.
TaBle 3 | cytokine gene expression levels and their combinations measured from PPD-stimulated PBMcs to discriminate patients with active TB 
from lTBi.
cytokine combination Positive active  
TB (n = 25)
Positive lTBi  
(n = 20)
sens.  
(%)
spec.  
(%)
aUc  
(ci 95%)
p
IFN-γ 11 3 44 85 0.598 (0.426–0.770) 0.263
IL-17 8 2 32 90 0.534 (0.363–0.705) 0.698
IL-4 8 2 32 90 0.662 (0.500–0.824) 0.064
IFN-γ + IL-17 + IL-4 12 3 48 85 0.586 (0.414–0.758) 0.326
IFN-γ + IL-17 12 3 48 85 0.551 (0.376–0.726) 0.560
IFN-γ + IL-4 9 3 36 80 0.623 (0.452–0.794) 0.160
IL4 + IL-17 11 3 44 85 0.594 (0.426–0.762) 0.283
IFN-γ or IL-17 or IL-4 16 5 64 75 n/a n/a
IFN-γ or IL-17 13 4 52 80 n/a n/a
IFN-γ or IL-4 15 4 60 80 n/a n/a
IL-17 or IL-4 12 4 48 80 n/a n/a
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FigUre 2 | Fold increases in iFn-γ (a), il-17 (B), and il-4 (c) mrna expression after PPD stimulation and the respective rOc curves with aUcs (ci 
95%). TB, n = 25; LTBI, n = 20; and BCG, n = 8. The cutoff values for each assay are shown with dashed lines and the medians of the gene expression levels for 
each group with horizontal bars.
FigUre 3 | Fold increase in iFn-γ, il-17, and il-4 mrna expression after PPD stimulation and the respective rOc curves with aUcs (ci 95%) 
calculated with TB and ra groups. TB, n = 25; RA, n = 11; MISC, n = 9; and BCG, n = 8. (a) IFN-γ, (B) IL-17, and (c) IL-4. Dashed lines represent the cutoff 
for each assay and the horizontal bars represent the medians of the gene expression level for each group.
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The ROC curves with AUCs for the IFN-γ, IL-17, and IL-4 
mRNA assays were constructed with the TB and RA groups, and 
the cutoffs were assessed to such a level where all the patients in 
the RA group remained below the cutoff line (Figure 3). With this 
approach, 48, 32, and 32% sensitivities were achieved in IFN-γ, 
IL-17, and IL-4 assays, respectively, for TB and RA groups. When 
the cumulative mRNA expressions were calculated, improved 
sensitivity up to 56% was found in most of the combinations 
(Table 4). Finally, the analysis of any positive result in at least one 
of the tests of IFN-γ, IL-17, or IL-4 resulted in the sensitivity of 
64% with 100% specificity.
DiscUssiOn
Distinguishing active TB from LTBI, particularly, in patients with 
underlying inflammatory conditions that may resemble the clini-
cal presentation of TB, remains an important clinical challenge. 
It is especially demanding in patients with a history of potential 
TaBle 4 | cytokine gene expression levels and their combinations measured from PPD-stimulated PBMcs to discriminate patients with active TB from 
lTBi with ra.
cytokine  
combination
Positive active  
TB (n = 25)
Positive lTBi + ra  
(n = 11)
sens.  
(%)
spec.  
(%)
aUc  
(ci 95%)
p
IFN-γ 12 0 48 100 0.733 (0.573–0.893) <0.05*
IL-17 8 0 32 100 0.620 (0.432–0.808) 0.264
IL-4 8 0 32 100 0.724 (0.552–0.895) <0.05*
IFN-γ + IL-17 + IL-4 14 0 56 100 0.720 (0.556–0.884) <0.05*
IFN-γ + IL-17 14 0 56 100 0.675 (0.501–0.848) 0.102
IFN-γ + IL-4 14 0 56 100 0.758 (0.603–0.914) <0.05*
IL-4 + IL-17 11 0 44 100 0.693 (0.518–0.867) 0.069
IFN-γ or IL-17 or IL-4 16 0 64 100 n/a n/a
IFN-γ or IL-17 13 0 52 100 n/a n/a
IFN-γ or IL-4 16 0 64 100 n/a n/a
IL-17 or IL-4 12 0 48 100 n/a n/a
*p < 0.05 was considered significant.
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exposure to TB who currently run fever of unknown cause and 
show elevated inflammatory markers, yet lack bacteriological 
confirmation of TB. Smear microscopy may not be sensitive, 
and culture takes too much time detecting Mtb. Nucleic acid 
amplification methods, even if sensitive, are expensive and not 
widely available. The IGRA techniques, although applicable to 
ex vivo detection of sensitized T lymphocytes, are not very useful 
in diagnosing active TB. Furthermore, at present, biomarkers or 
a diagnostic test does not exist to predict disease activation in 
immunosuppressed individuals. Here, we present the investiga-
tion of the quantitative expressions of IFN-γ, IL-17, and IL-4, 
the cytokines presenting the major pathways of CD4+ cells dif-
ferentiation after antigenic stimulus. In our study, the combined 
quantitative analysis of genes coding for IFN-γ, IL-17, and IL-4 
proteins from the PPD-stimulated PBMCs distinguished active 
TB from LTBI with concomitant miscellaneous inflammatory 
conditions only moderately. When each cytokine was analyzed 
independently, the differences between the groups were not 
found statistically significant. The cumulative expression of 
IFN-γ, IL-17, and IL-4, or IFN-γ and IL-17, resulted in 48% 
sensitivity with 85% specificity remaining below the desired 
specifications for a clinical test. Alternatively, when any of the 
tests for IFN-γ, IL-17, or IL-4 was over the cutoff, the assay 
showed a sensitivity of 64% and specificity of 75%. When disease 
stage discriminating ability of IFN-γ, IL-17, and IL-4 were tested 
with a more homogeneous LTBI group, namely the RA group, 
the combined analysis of IFN-γ, IL-17, and IL-4 or IFN-γ and 
IL-4 resulted in 64% sensitivity (p < 0.05) with 100% specificity. 
Thus, scrutinizing the patients groups into more homogenous 
ones, we were able to improve the discrimination power of 
the cytokine measurement. Nonetheless, we want to underline 
the inevitable fact that in the real clinical situation, when the 
diagnosis of a patient has remained unclear, the clinician is 
expecting to get from a laboratory a definitive interpretation 
regarding each individual sample, but not statistics. In our 
opinion, proper diagnostic method should be robust enough to 
categorize patients into groups. Statistical significance between 
the groups is in fact not sufficient to qualify any method as a 
diagnostic tool.
A feature that adds weight to our study is the enrollment of 
LTBI patients with other underlying diseases, such as rheuma-
toid diseases. In many previous studies (14, 16, 24), LTBI group 
has been represented by household contacts (HHC). Selecting, 
instead, LTBI group members among subjects with underlying 
inflammatory conditions is expected to be more challenging from 
the clinical standpoint. These patients, similar to those with active 
TB, have a systemic inflammatory condition, which indicates 
a priori a misbalanced cytokine production (25, 26).
The usefulness of a variety of immunological biomarkers 
in TB infection has been extensively investigated during last 
decades. The controversy regarding the applicability of any 
marker may partly be due to a great variety of methodologies. 
In some studies, cell subpopulation frequencies were meas-
ured (27), while in others cell phenotypical or functional 
profiles were studied (28), and yet in some others, cytokine 
production levels were measured with ELISA (24) or (18), like 
in our study, gene expression levels coding certain proteins 
were quantified.
One of the limitations of the study includes the relatively 
small cohorts of tested individuals and the great variability in the 
spectrum of underlying diseases in the MISC group. The degree 
of immunosuppression varied between the patients. However, 
none of the patients presented such a degree of immunosuppres-
sion that it would have prevented immunoreactivity in IGRA 
tests.
In many studies (including ours), the duration of anti-TB 
therapy in TB patients is variable, which may be a confounding 
factor. We attempted to standardize the duration of the anti-TB 
therapy by only enrolling patients having received treatment for 
no longer than 2 weeks (median: 7 days, range: 0–14 days).
Limited repertoire of the tested genes is another limitation of 
our study, but we aimed to test only the mainstream markers of 
T cell differentiation.
In real practice, LTBI patients requiring differential diag-
nostics from active TB are a highly heterogenic group. Each 
condition within this group may present with a different degree 
of cytokine misbalance. LTBI group can comprise either HHC 
(practically healthy) or patients with RA with highly dysregulated 
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cytokine and chemokine production. An additional challenge in 
trying to find sustainable immunological signatures lies in the 
nature of the TB infection, which is by no means a homogenous 
condition. Studies of cynomolgus macaques have shown that 
there is a wide spectrum of overlapping stages of infection 
presenting with different degrees of tissue damage and immune 
responses (29). According to this novel understanding, active TB 
is a continuum of LTBI or subclinical TB. Therefore, it appears 
imperative that future search for new immunological signatures 
be linked with the results of modern imaging tests (e.g., positron 
emission tomography) or other imaging techniques estimating 
the severity or current stage of lung pathology (30). Infection 
stage differentiation will most probably require simultaneous 
analysis of multiple markers underscoring the regulation of vari-
ous genes (genomics) or protein expression profiles (proteomics) 
(18, 24, 31). These findings should be linked, e.g., to the types 
of granulomas and the location and viability of the bacillus in 
different outcomes of TB.
Contrary to our findings, IFN-γ mRNA expression levels 
have been reported to be significantly higher in LTBI than TB 
patients, when the cells are stimulated with the recombinant 
ESAT-6 (18). The IFN-γ mRNA expression levels have been 
correlated with the production of the corresponding protein by 
the cells stimulated in the QuantiFeron® tubes (32). In accordance 
with our findings, ESAT-6 and CFP-10 protein stimulation has 
not proved as efficient as the PPD stimulation (11, 24, 33). Our 
study showed that expression levels of the major genes associated 
with T-cell differentiation only moderately discriminated active 
TB from LTBI. As a stimulus, we used PPD for the reason that, 
in active TB, bacterial load is higher and, in replicating bacteria, 
antigen expression is more variable than, e.g., by dormant bacte-
ria of LTBI (34). Higher variability of antigens better diversifies 
immune response resulting in proliferation of T-cell clones with a 
wider receptor repertoire. Stimulation with PPD therefore better 
targets all reactive T-cell clones than, e.g., stimulation with only 
ESAT-6 or CFP-10.
An increased IL-17 mRNA expression has been described in 
mononuclear cells from pleural fluid of patients with tuberculous 
pleurisy (21). Compared to the healthy controls, increased IL-17 
mRNA expression levels have also been found from TB patients’ 
unstimulated PBMCs (33). In our study, antigen-stimulated 
IL-17 mRNA expression was associated with active TB, rather 
than with LTBI.
Variable expressions of IL-4 and IL4δ2 mRNAs have been 
reported in the groups of active TB, LTBI, or HHCs from unstim-
ulated cells (13, 14). Furthermore, the ratios of IL-4 to IL-4δ2 or 
IFN-γ of the mRNA expression levels have been suggested as a 
cure indicator (13, 16). We also detected elevated IL-4 mRNA 
expression levels in patients with active TB.
The IL-4δ2 gene was expressed at very low levels even after 
stimulation. Therefore, it was omitted from further analysis.
Rises in FoxP3 mRNA expression and expansion of Treg cells 
have also reported to be more common in patients with active 
TB than in those with the LTBI (11, 18). Our data did not reveal 
differences between the FoxP3 mRNA expression levels.
As a conclusion, we chose to explore the potential of combined 
quantitative expression profiling of some main markers of T cell 
activation and differentiation, IFN-γ, IL-17, and IL-4 mRNA, 
to discriminate between active TB and LTBI in clinical patient 
groups. A clinical setting is demanding as such, yet these are 
the patient groups representing the greatest challenge in clinical 
practice.
Presented results suggest that the undertaken approach seems 
to have only a moderate diagnostic value to qualify for routine 
use. Alternative approaches, probably based on pathogen-related 
biomarkers, should be exploited.
aUThOr cOnTriBUTiOns
LS: designed the study, collected clinical samples, performed 
the analyses, interpreted the data, and wrote the first draft. 
AKa: collected clinical samples and applied for the ethical clear-
ances. AKn, LP, RK, and HV: collected clinical samples. TT: 
designed the study, applied for the ethical clearances, and wrote 
the first draft. All authors contributed to the manuscript prepara-
tion, read, approved, and accepted the final version.
acKnOWleDgMenTs
This study was supported by the Tuberculosis Association of the 
University of Tampere, the Nummela Sanatorium Association, 
the Foundation of the Finnish Anti-Tuberculosis Association, 
the Research foundation of the pulmonary diseases, the Väinö 
and Laina Kivi Foundation, and Orion Research Foundation. 
We want to thank HUSLAB (Helsinki), the Department of 
Mycobacteriology, for help in recruiting the TB patients.
reFerences
1. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol (2001) 
19:93–129. doi:10.1146/annurev.immunol.19.1.93 
2. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the 
diagnosis of latent tuberculosis infection: an update. Ann Intern Med (2008) 
149:177–84. doi:10.7326/0003-4819-149-3-200808050-00241 
3. Lavender TW, Barrett A, Magee J, Ong EL, et al. Interferon-gamma release 
assays in the diagnosis of active tuberculosis disease in a low-incident 
setting: a 5-year review of data. Clin Microbiol Infect (2013) 19:1078–81. 
doi:10.1111/1469-0691.12129 
4. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et  al. 
Safety of synthetic and biological DMARDs: a systematic literature review 
informing the 2013 update of the EULAR recommendations for management 
of rheumatoid arthritis. Ann Rheum Dis (2014) 73:529–35. doi:10.1136/
annrheumdis-2013-204575 
5. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, 
et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage dis-
tinct from the T helper type 1 and 2 lineages. Nat Immunol (2005) 6:1123–32. 
doi:10.1038/ni1254 
6. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, 
et  al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ 
T cell responses after vaccination and during Mycobacterium tuberculosis 
challenge. Nat Immunol (2007) 8:369–77. doi:10.1038/ni1449 
7. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth 
Factor Rev (2010) 21:455–62. doi:10.1016/j.cytogfr.2010.10.004 
9Savolainen et al. Cytokine mRNA in tuberculosis patients 
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 239
8. Belkaid Y, et al. Role of Foxp3-positive regulatory T cells during infection. Eur 
J Immunol (2008) 38:918–21. doi:10.1002/eji.200738120 
9. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB. Pathogen-
specific regulatory T cells delay the arrival of effector T cells in the lung 
during early tuberculosis. J Exp Med (2010) 207:1409–20. doi:10.1084/
jem.20091885 
10. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory 
T cells are expanded in blood and disease sites in patients with tuber-
culosis. Am J Respir Crit Care Med (2006) 173:803–10. doi:10.1164/
rccm.200508-1294OC 
11. Marin ND, París SC, Vélez VM, Rojas CA, Rojas M, García LF. Regulatory 
T cell frequency and modulation of IFN-gamma and IL-17 in active and 
latent tuberculosis. Tuberculosis (Edinb) (2010) 90:252–61. doi:10.1016/j.
tube.2010.05.003 
12. Rook GA, Hernandez-Pando R, Dheda K, Teng Seah G. IL-4 in tubercu-
losis: implications for vaccine design. Trends Immunol (2004) 25:483–8. 
doi:10.1016/j.it.2004.06.005 
13. Dheda K, Chang JS, Breen RA, Kim LU, Haddock JA, Huggett JF, et al. In vivo 
and in  vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary 
tuberculosis. Am J Respir Crit Care Med (2005) 172:501–8. doi:10.1164/
rccm.200502-278OC 
14. Demissie A, Wassie L, Abebe M, Aseffa A, Rook G, Zumla A, et  al. The 
6- kilodalton early secreted antigenic target-responsive, asymptomatic contacts 
of tuberculosis patients express elevated levels of interleukin-4 and reduced 
levels of gamma interferon. Infect Immun (2006) 74:2817–22. doi:10.1128/
IAI.74.5.2817-2822.2006 
15. Demissie A, Abebe M, Aseffa A, Rook G, Fletcher H, Zumla A, et al. Healthy 
individuals that control a latent infection with Mycobacterium tuberculosis 
express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. 
J Immunol (2004) 172:6938–43. doi:10.4049/jimmunol.172.11.6938 
16. Wassie L, Demissie A, Aseffa A, Abebe M, Yamuah L, Tilahun H, et al. Ex vivo 
cytokine mRNA levels correlate with changing clinical status of ethiopian TB 
patients and their contacts over time. PLoS One (2008) 3:e1522. doi:10.1371/
journal.pone.0001522 
17. Lenarczyk A, Helsloot J, Farmer K, Peters L, Sturgess A, Kirkham B. 
Antigen-induced IL-17 response in the peripheral blood mononuclear 
cells (PBMC) of healthy controls. Clin Exp Immunol (2000) 122:41–8. 
doi:10.1046/j.1365-2249.2000.01328.x 
18. Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM, et al. 
Messenger RNA expression of IL-8, FOXP3, and IL-12beta differentiates 
latent tuberculosis infection from disease. J Immunol (2007) 178:3688–94. 
doi:10.4049/jimmunol.178.6.3688 
19. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation 
of housekeeping genes for normalizing RNA expression in real-time PCR. 
Biotechniques (2004) 37:112–9. 
20. Roberts T, Beyers N, Aguirre A, Walzl G. Immunosuppression during active 
tuberculosis is characterized by decreased interferon-gamma production 
and CD25 expression with elevated forkhead box P3, transforming growth 
factor-beta, and interleukin-4 mRNA levels. J Infect Dis (2007) 195:870–8. 
doi:10.1086/511277 
21. Qiao D, Yang BY, Li L, Ma JJ, Zhang XL, Lao SH, et al. ESAT-6- and CFP-
10-specific Th1, Th22 and Th17 cells in tuberculous pleurisy may contribute 
to the local immune response against Mycobacterium tuberculosis infec-
tion. Scand J Immunol (2011) 73:330–7. doi:10.1111/j.1365-3083.2011. 
02512.x 
22. Burl S, Hill PC, Jeffries DJ, Holland MJ, Fox A, Lugos MD, et al. FOXP3 gene 
expression in a tuberculosis case contact study. Clin Exp Immunol (2007) 
149:117–22. doi:10.1111/j.1365-2249.2007.03399.x 
23. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative 
C(T) method. Nat Protoc (2008) 3:1101–8. doi:10.1038/nprot.2008.73 
24. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of 
TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease 
and latent infection in a West African cohort. PLoS One (2010) 5:e12365. 
doi:10.1371/journal.pone.0012365 
25. Aerts NE, De Knop KJ, Leysen J, Ebo DG, Bridts CH, Weyler JJ, et al. Increased 
IL-17 production by peripheral T helper cells after tumour necrosis factor 
blockade in rheumatoid arthritis is accompanied by inhibition of migra-
tion-associated chemokine receptor expression. Rheumatology (Oxford) 
(2010) 49:2264–72. doi:10.1093/rheumatology/keq224 
26. Pavlovic V, Dimic A, Milenkovic S, Krtinic D, et al. Serum levels of IL-17, IL-4, 
and INFgamma in Serbian patients with early rheumatoid arthritis. J Res Med 
Sci (2014) 19:18–22. 
27. Chen X, Zhang M, Liao M, Graner MW, Wu C, Yang Q, et al. Reduced Th17 
response in patients with tuberculosis correlates with IL-6R expression on 
CD4+ T Cells. Am J Respir Crit Care Med (2010) 7:734–42. doi:10.1164/
rccm.200909-1463OC
28. Marín ND, París SC, Rojas M, García LF. Reduced frequency of memory T 
cells and increased th17 responses in patients with active tuberculosis. Clin 
Vaccine Immunol (2012) 19:1667–76. doi:10.1128/CVI.00390-12 
29. Gideon HP, Flynn JL. Latent tuberculosis: what the host “sees”? Immunol Res 
(2011) 50:202–12. doi:10.1007/s12026-011-8229-7 
30. Barry CE III, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum 
of latent tuberculosis: rethinking the biology and intervention strategies. Nat 
Rev Microbiol (2009) 7:845–55. doi:10.1038/nrmicro2236 
31. Lu C, Wu J, Wang H, Wang S, Diao N, Wang F, et  al. Novel biomarkers 
distinguishing active tuberculosis from latent infection identified by gene 
expression profile of peripheral blood mononuclear cells. PLoS One (2011) 
6:e24290. doi:10.1371/journal.pone.0024290 
32. Kim S, Kim YK, Lee H, Cho JE, Kim HY, Uh Y, et al. Interferon gamma mRNA 
quantitative real-time polymerase chain reaction for the diagnosis of latent 
tuberculosis: a novel interferon gamma release assay. Diagn Microbiol Infect 
Dis (2013) 75:68–72. doi:10.1016/j.diagmicrobio.2012.09.015 
33. Marín ND, París SC, Rojas M, García LF. Functional profile of CD4+ and 
CD8+ T cells in latently infected individuals and patients with active TB. 
Tuberculosis (Edinb) (2013) 93:155–66. doi:10.1016/j.tube.2012.12.002 
34. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, et al. Quantitative 
comparison of active and latent tuberculosis in the cynomolgus macaque 
model. Infect Immun (2009) 77:4631–42. doi:10.1128/IAI.00592-09 
Conflict of Interest Statement: The authors declare that they have no conflict 
of interests. Preliminary results of this study were reported as a poster at annual 
meeting of Nordic Society of Clinical microbiology and Infectious Diseases, 2013.
Copyright © 2016 Savolainen, Kantele, Knuuttila, Pusa, Karttunen, Valleala and 
Tuuminen. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
